What question did this study set out to answer?

To evaluate the immunopharmacologic response, lymphocyte kinetics, and cytokine profiles in patients with minimal residual disease-positive B-lineage acute lymphoblastic leukemia receiving continuous blinatumomab infusion.

May 17, 2012Blood

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

View Full Paper

Ask AI

Bookmark

Authors

MKMatthias KlingerGoethe University Frankfurt CBChristian BrandlAmgen (Germany)GZGerhard ZugmaierPhilipps University of Marburg

Discussion

Member takes

Implication

Clinical trial reveals rapid B-cell clearance and robust T-cell expansion during continuous blinatumomab infusion in B-ALL, highlighting its distinct mechanism of action.

Key Points

To evaluate the immunopharmacologic response, lymphocyte kinetics, and cytokine profiles in patients with minimal residual disease-positive B-lineage acute lymphoblastic leukemia receiving continuous blinatumomab infusion.
Phase 2 clinical trial (NCT00560794) evaluating continuous intravenous infusion of CD19/CD3-bispecific BiTE antibody blinatumomab in patients with MRD(+) B-ALL.
Tracked circulating B-cell and T-cell kinetics, CD69 activation marker expression on CD4(+) and CD8(+) subsets, and serum cytokine levels across treatment cycles.
B-cell counts dropped to < 1 cell/μL within an average of 2 days and remained undetectable throughout treatment.
T-cell counts nadired within < 1 day, recovered within days, and expanded on average to > 2-fold above baseline within 2 to 3 weeks of continuous infusion.
CD4(+) and CD8(+) T cells exhibited de novo CD69 activation, accompanied by an initial transient release of IL-10, IL-6, and IFN-γ that did not recur upon starting cycle 2.

Cite This Study

Klinger et al. (2012) studied this question.

synapsesocial.com/papers/6a0f8242fa36b6e053fcbb01 https://doi.org/10.1182/blood-2012-01-400515

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial reveals rapid B-cell clearance and robust T-cell expansion during continuous blinatumomab infusion in B-ALL, highlighting its distinct mechanism of action.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Discussion

Member takes

Implication

Key Points

Cite This Study

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider